This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chow, A. T.
Right arrow Articles by Natarajan, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chow, A. T.
Right arrow Articles by Natarajan, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2001, p. 2122-2125, Vol. 45, No. 7
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.7.2122-2125.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Safety and Pharmacokinetics of Multiple 750-Milligram Doses of Intravenous Levofloxacin in Healthy Volunteers

Andrew T. Chow,* Cynthia Fowler, R. Rex Williams, Nancy Morgan, Susan Kaminski, and Jaya Natarajan

The Robert Wood Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869

Received 10 August 2000/Returned for modification 29 January 2001/Accepted 3 April 2001

The safety and pharmacokinetics of a once-daily high intravenous dose of levofloxacin (750 mg) in 18 healthy volunteers were studied in a double-blind, randomized, placebo-controlled, single-center parallel group study. Levofloxacin was well tolerated, and higher maximum concentration of drug in serum and area under the concentration-time curve values were achieved. For difficult-to-treat infections, high daily doses of levofloxacin may be beneficial, and intravenous administration may be preferred in certain clinical settings, such as when treating patients in intensive care units, warranting further evaluation.

* Corresponding author. Mailing address: The R.W. Johnson Pharmaceutical Research Institute, Department of Clinical Drug Metabolism, 1000 Route 202 South, Raritan, NJ 08869-0602. Phone: (908) 704-4057. Fax: (908) 253-0448. E-mail: achow{at}prius.jnj.com.

Antimicrobial Agents and Chemotherapy, July 2001, p. 2122-2125, Vol. 45, No. 7
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.7.2122-2125.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Muller-Serieys, C., Saleh Mghir, A., Massias, L., Fantin, B. (2009). Bactericidal Activity of the Combination of Levofloxacin with Rifampin in Experimental Prosthetic Knee Infection in Rabbits Due to Methicillin-Susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 2145-2148 [Abstract] [Full Text]  
  • DeFife, R., Scheetz, M. H., Feinglass, J. M., Postelnick, M. J., Scarsi, K. K. (2009). Effect of Differences in MIC Values on Clinical Outcomes in Patients with Bloodstream Infections Caused by Gram-Negative Organisms Treated with Levofloxacin. Antimicrob. Agents Chemother. 53: 1074-1079 [Abstract] [Full Text]  
  • Murillo, O., Pachon, M. E., Euba, G., Verdaguer, R., Tubau, F., Cabellos, C., Cabo, J., Gudiol, F., Ariza, J. (2008). Antagonistic Effect of Rifampin on the Efficacy of High-Dose Levofloxacin in Staphylococcal Experimental Foreign-Body Infection. Antimicrob. Agents Chemother. 52: 3681-3686 [Abstract] [Full Text]  
  • Murillo, O., Domenech, A., Garcia, A., Tubau, F., Cabellos, C., Gudiol, F., Ariza, J. (2006). Efficacy of High Doses of Levofloxacin in Experimental Foreign-Body Infection by Methicillin-Susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 4011-4017 [Abstract] [Full Text]  
  • Kiser, T. H., Hoody, D. W., Obritsch, M. D., Wegzyn, C. O., Bauling, P. C., Fish, D. N. (2006). Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.. Antimicrob. Agents Chemother. 50: 1937-1945 [Abstract] [Full Text]  
  • Campion, J. J., Chung, P., McNamara, P. J., Titlow, W. B., Evans, M. E. (2005). Pharmacodynamic Modeling of the Evolution of Levofloxacin Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 2189-2199 [Abstract] [Full Text]  
  • Dupont, P., Hocquet, D., Jeannot, K., Chavanet, P., Plesiat, P. (2005). Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa. J Antimicrob Chemother 55: 518-522 [Abstract] [Full Text]  
  • Sprandel, K. A., Schriever, C. A., Pendland, S. L., Quinn, J. P., Gotfried, M. H., Hackett, S., Graham, M. B., Danziger, L. H., Rodvold, K. A. (2004). Pharmacokinetics and Pharmacodynamics of Intravenous Levofloxacin at 750 Milligrams and Various Doses of Metronidazole in Healthy Adult Subjects. Antimicrob. Agents Chemother. 48: 4597-4605 [Abstract] [Full Text]  
  • Overholser, B. R., Kays, M. B., Forrest, A., Sowinski, K. M. (2004). Sex-Related Differences in the Pharmacokinetics of Oral Ciprofloxacin. J Clin Pharmacol 44: 1012-1022 [Abstract] [Full Text]  
  • Rodvold, K. A., Danziger, L. H., Gotfried, M. H. (2003). Steady-State Plasma and Bronchopulmonary Concentrations of Intravenous Levofloxacin and Azithromycin in Healthy Adults. Antimicrob. Agents Chemother. 47: 2450-2457 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»